

(19) World Intellectual Property
Organization

International Bureau

(43) International Publication Date
11 March 2021 (11.03.2021)(10) International Publication Number
WO 2021/046407 A8

(51) International Patent Classification:

C07D 413/14 (2006.01) A61P 37/00 (2006.01)
C07D 413/12 (2006.01) A61K 31/553 (2006.01)

(21) International Application Number:

PCT/US2020/049487

(22) International Filing Date:

04 September 2020 (04.09.2020)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

62/897,223 06 September 2019 (06.09.2019) US
62/932,404 07 November 2019 (07.11.2019) US
63/001,016 27 March 2020 (27.03.2020) US
63/004,319 02 April 2020 (02.04.2020) US
63/004,290 02 April 2020 (02.04.2020) US
63/004,301 02 April 2020 (02.04.2020) US

(71) Applicant: **RIGEL PHARMACEUTICALS, INC.**
[US/US]; 1180 Veterans Boulevard, South San Francisco,
California 94080 (US).

(72) Inventors: **CHEN, Yan**; c/o Rigel Pharmaceuticals, Inc.,
1180 Veterans Boulevard, South San Francisco, Califor-
nia 94080 (US). **YU, Jiaxin**; c/o Rigel Pharmaceuticals,
Inc., 1180 Veterans Boulevard, South San Francisco, Cali-
fornia 94080 (US). **SHAW, Simon**; c/o Rigel Pharmaceu-
ticals, Inc., 1180 Veterans Boulevard, South San Francis-
co, California 94080 (US). **DARWISH, Ihab**; c/o Rigel
Pharmaceuticals, Inc., 1180 Veterans Boulevard, South San
Francisco, California 94080 (US). **TAYLOR, Vanessa**; c/
o Rigel Pharmaceuticals, Inc., 1180 Veterans Boulevard,
South San Francisco, California 94080 (US). **BHAMIDI-
PATI, Somasekhar**; c/o Rigel Pharmaceuticals, Inc., 1180
Veterans Boulevard, South San Francisco, California 94080
(US). **LUO, Zhushou**; c/o Rigel Pharmaceuticals, Inc.,
1180 Veterans Boulevard, South San Francisco, California
94080 (US). **KOLLURI, Rao**; c/o Rigel Pharmaceuticals,
Inc., 1180 Veterans Boulevard, South San Francisco, Cali-
fornia 94080 (US).

(74) Agent: **LENTZ, Nelsen, L.** et al.; c/o Eli Lilly and Compa-
ny, P.O. Box 6288, Indianapolis, IN 46206-6288 (US).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,

DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,
HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN,
KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD,
ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO,
NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW,
SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN,
TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ,
UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,
TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,
MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- with information concerning authorization of rectification
of an obvious mistake under Rule 91.3 (b) (Rule 48.2(i))

(48) Date of publication of this corrected version:

24 February 2022 (24.02.2022)

(15) Information about Correction:

see Notice of 24 February 2022 (24.02.2022)

(54) Title: RIPI INHIBITORY COMPOUNDS AND METHODS FOR MAKING AND USING THE SAME

(57) Abstract: Disclosed herein are kinase inhibitory compounds, such as a receptor-interacting protein-1 (RIP1) kinase inhibitor com-
pounds, as well as pharmaceutical compositions and combinations comprising such inhibitory compounds. The disclosed compounds,
pharmaceutical compositions, and/or combinations may be used to treat or prevent a kinase-associated disease or condition, particularly
a RIP1-associated disease or condition.